ArticleBritish journal of cancer2020
Diagnostic value of
Article in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- The Role of Glucose Transporters in Oral Squamous Cell Carcinoma.Biomolecules · 2021Pooled it
- Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study.British journal of cancer · 2024Trial
- Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers.JAMA otolaryngology-- head & neck surgery · 2022Trial
- Association of SUVmax and never-smoker/never- or minimally-drinker history with PD-L1 expression in resected oral squamous cell carcinoma: a nodal-status-stratified analysis.Annals of nuclear medicine · 2026Article
- Treatment strategy for cervical lymph node metastases in patients with lower gingival carcinoma undergoing mandibular marginal resection.Oral and maxillofacial surgery · 2026Article
- Comparison ofCancer science · 2025Article
- CD8JCO precision oncology · 2024Review
- Lymph nodes rather than pleural metabolic activity inTranslational lung cancer research · 2024Article
- Induction of Peroxiredoxin 1 by Hypoxia Promotes Cellular Autophagy and Cell Proliferation in Oral Leukoplakia via HIF-1α/BNIP3 Pathway.Journal of molecular histology · 2024Article
- Development of a novel lncRNA-derived immune gene score using machine learning-based ensembles for predicting the survival of HCC.Journal of cancer research and clinical oncology · 2024Article
- The Role of Tumor Metabolic Reprogramming in Tumor Immunity.International journal of molecular sciences · 2023Review
- The Significance of Microenvironmental and Circulating Lactate in Breast Cancer.International journal of molecular sciences · 2023Review
- Immune checkpoint inhibition: a future guided by radiology.The British journal of radiology · 2023Review
- Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in liver metastasis lesions after colon radical operation.BMC cancer · 2023Article
- Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations.Cell communication and signaling : CCS · 2023Review
- Tumor infiltrating lymphocytes and radiological picture of the tumor.Medical oncology (Northwood, London, England) · 2023Review
- Review
- Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2023Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLately, immune checkpoint proteins, such as programmed death 1 (PD-1) and its ligand-1 (PD-L1), have garnered attention as a new target in oral squamous cell carcinoma (OSCC). Reportedly, fluoro-D-glucose (FDG)-uptake alteration by anti-PD-1 antibody treatment depicts the response in patients with lung cancer. This study aims to elucidate the correlations between tumour immune status, clinicopathological factors,
methodsWe performed immunohistochemical analysis of PD-L1, hypoxia-inducible factor 1 A (HIF-1A), glucose transporter type 1 (GLUT1), CD8, E-cadherin and Ki-67 on 59 operable OSCC samples. We assessed the correlations between these factors and preoperative
resultsLow expression of PD-L1 in OSCC correlated with cancer aggressiveness, poor prognosis, high
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.